In the present study, the patients with EGFR wild-type might also show high phosphorylated EGFR expression, which may account for why 10–20% of NSCLC patients in absence of EGFR mutation have responded to treatment with gefitinib or erlotinib. Here, EGFR is linked to non-small cell lung carcinoma.